Introduction to Biopharmaceutics and its Role in Drug Development
In the world of drug development, the meaning of the term “biopharmaceutics” often evokes confusion, even among scientists and professionals who work in the field. “Pharmaceutics” narrowly defined is a field of science that involves the preparation, use, or dispensing of medicines (Woolf, 1981). Addition of the pre- fix “bio,” coming from the Greek “bios,” relating to living organisms or tissues (Woolf, 1981), expands this field into the science of preparing, using, and administering drugs to living organisms or tissues. Inherent in the concept of biopharmaceutics as discussed here is the interdependence of biological aspects of the living organism (the patient) and the physical–chemical principles that govern the preparation and behavior of the medicinal agent or drug product.
KeywordsDissolution Rate Dosage Form Drug Product Solid Dispersion Active Pharmaceutical Ingredient
Unable to display preview. Download preview PDF.
- FDA (U.S. Food and Drug Administration) Guidance Documents for Industry, 1995, Rockville. Guidance for Industry. Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (November 1995); http://www.fda.gov/cder/guidance/cmc5.pdf.
- FDA (U.S. Food and Drug Administration) Guidance for Industry, 2000, Rockville. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products -General Considerations (October 2000); http://www.fda.gov/cder/guidance/3615fnl.pdf. FDA (U.S. Food and Drug Administration) Guidance for Industry, 2005, Rockville.
- The Biopharmaceutics Classification System (BCS) Guidance (June 2005); http://www.fda.gov/cder/OPS/BCS guidance.htm.
- Gennaro, A. R. (ed.). (1995). Remington: The Science and Practice of Pharmacy, 19th ed. Mack Publishing Co., Easton, PA.Google Scholar
- Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics,2nd ed. Marcel Dekker Inc., New York.Google Scholar
- Han, H. K. and Amidon, G. L. (2000). Targeted prodrug design to optimize drug delivery. AAPS PharmSci. (online). 2(1): article 6.Google Scholar
- Higuchi, T. (1958). Some physical chemical aspects of suspension formulation. J. Am. Pharm. Assoc. 47:657-660.Google Scholar
- Higuchi, T., Szulczewski, D. H., and Yunker, M. (1956). Physical chemical properties and ultraviolet spectral characteristics of amyl nitrite. J. Am. Pharm. Assoc. 45:776-779.Google Scholar
- Higuchi, W. I., Parrott, E. L., Wurster, D. E., and Higuchi, T. (1958). Investigation of drug release from solids. II. Theoretical and experimental study of influences of bases and buffers on rates of dissolution of acidic solids. J. Am. Pharm. Assoc. 47:376-383.Google Scholar
- Hilgers, A. R., Smith, D. P., Biermacher, J. J., Day, J. S., Jensen, J. L., Sims, S. M., Adams, W. J., Friis, J. M., Palandra, J., Hosley, J. D., Shobe, E. M., and Burton, P. S. (2003). Predicting oral absorption of drugs: a case study with a novel class of antimicrobial agents. Pharm. Res. 20:1149-1155.CrossRefPubMedGoogle Scholar
- Kalgutkar, A. S., Vaz, A. D., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., and Hop, C. E. (2005). Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33:243-253.CrossRefPubMedGoogle Scholar
- Kostenbauder, H. B. and Higuchi, T. (1957). A note on the water solubility of some N , N ,-dialkylamides. J. Am. Pharm. Assoc. 46:205-206.Google Scholar
- Porter, C. J., Kaukonen, A. M., Boyd, B. J., Edwards, G. A., and Charman, W. N. (2004). Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 21:1405-1412.CrossRefPubMedGoogle Scholar
- Reinstein, J. A. and Higuchi, T. (1958). Examination of the physical chemical basis for the isoniazid-p-aminosalicylic acid combination. J. Am. Pharm. Assoc. 47:749-752.Google Scholar
- Rowland, M. and Tozer, T. N. (1989). Clinical Pharmacokinetics: Concepts and Applications, 2nd ed. Lea & Febiger, Philadelphia.Google Scholar
- Shou, M., Lin, Y., Lu, P., Tang, C., Mei, Q., Cui, D., Tang, W., Ngui, J. S., Lin, C. C., Singh, R., Wong, B. K., Yergey, J. A., Lin, J. H., Pearson, P. G., Baillie, T. A., Rodrigues, A. D., and Rushmore, T. H. (2001). Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:17-36.CrossRefPubMedGoogle Scholar
- Sun, D., Yu, L. X., Hussain, M. A., Wall, D. A., Smith, R. L., and Amidon, G. L. (2004). In vitro testing of drug absorption for drug ‘developability’ assessment: forming an inter-face between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discov.Devel. 7:75-85.PubMedGoogle Scholar
- Verreck, G., Vandecruys, R., De Conde, V., Baert, L., Peeters, J., and Brewster, M. E. (2004). The use of three different solid dispersion formulations - melt extrusion, film-coated beads, and a glass thermoplastic system - to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J. Pharm. Sci. 93:1217-1228.CrossRefPubMedGoogle Scholar
- Woolf, H. B. (ed.). (1981). Webster’s New Collegiate Dictionary, G. & C. Merriam Co., Springfield.Google Scholar